Compare DHX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | BDTX |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.3M | 171.9M |
| IPO Year | 2007 | 2020 |
| Metric | DHX | BDTX |
|---|---|---|
| Price | $4.21 | $2.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.25 | ★ $9.67 |
| AVG Volume (30 Days) | 203.3K | ★ 607.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $127,826,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $42.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $1.60 |
| 52 Week High | $4.50 | $4.94 |
| Indicator | DHX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 62.58 |
| Support Level | $3.39 | $1.96 |
| Resistance Level | $4.18 | $2.26 |
| Average True Range (ATR) | 0.34 | 0.10 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 70.72 | 84.11 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.